BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 36017777)

  • 1. Muscle strength, but not body mass index, is associated with mortality in patients with non-alcoholic fatty liver disease.
    Charatcharoenwitthaya P; Karaketklang K; Aekplakorn W
    J Cachexia Sarcopenia Muscle; 2022 Oct; 13(5):2393-2404. PubMed ID: 36017777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver-related Mortality is Increased in Lean Subjects with Non- alcoholic Fatty Liver Disease Compared to Overweight and Obese Subjects.
    Feldman A; Wernly B; Strebinger G; Eder SK; Zandanell S; Niederseer D; Strasser M; Haufe H; Sotlar K; Paulweber B; Datz C; Aigner E
    J Gastrointestin Liver Dis; 2021 Sep; 30(3):366-373. PubMed ID: 34375373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population.
    Feng RN; Du SS; Wang C; Li YC; Liu LY; Guo FC; Sun CH
    World J Gastroenterol; 2014 Dec; 20(47):17932-40. PubMed ID: 25548491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obesity and muscle strength as long-term determinants of all-cause mortality--a 33-year follow-up of the Mini-Finland Health Examination Survey.
    Stenholm S; Mehta NK; Elo IT; Heliövaara M; Koskinen S; Aromaa A
    Int J Obes (Lond); 2014 Aug; 38(8):1126-32. PubMed ID: 24232499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low muscle mass and low muscle strength associate with nonalcoholic fatty liver disease.
    Gan D; Wang L; Jia M; Ru Y; Ma Y; Zheng W; Zhao X; Yang F; Wang T; Mu Y; Zhu S
    Clin Nutr; 2020 Apr; 39(4):1124-1130. PubMed ID: 31053512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural History of Nonalcoholic Fatty Liver Disease With Normal Body Mass Index: A Population-Based Study.
    Ahmed OT; Gidener T; Mara KC; Larson JJ; Therneau TM; Allen AM
    Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1374-1381.e6. PubMed ID: 34265444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease.
    Arvind A; Henson JB; Osganian SA; Nath C; Steinhagen LM; Memel ZN; Donovan A; Balogun O; Chung RT; Simon TG; Corey KE
    Hepatol Commun; 2022 Feb; 6(2):309-319. PubMed ID: 34558862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adiponectin-leptin ratio for the early detection of lean non-alcoholic fatty liver disease independent of insulin resistance.
    Lu CW; Yang KC; Chi YC; Wu TY; Chiang CH; Chang HH; Huang KC; Yang WS
    Ann Med; 2023 Dec; 55(1):634-642. PubMed ID: 36790383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-obese or lean non-alcoholic fatty liver disease was associated with increased risk of cancer in patients with type 2 diabetes mellitus.
    Chen N; Zhou J; Wang K; Li X; Li Z
    BMJ Open Diabetes Res Care; 2023 Feb; 11(1):. PubMed ID: 36792168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Muscle Strength with Non-Alcoholic Fatty Liver Disease in Korean Adults.
    Lee SB; Kwon YJ; Jung DH; Kim JK
    Int J Environ Res Public Health; 2022 Feb; 19(3):. PubMed ID: 35162699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Characteristics and Metabolic Profiles of Non-Alcoholic Fatty Liver Disease (NAFLD) in Lean Patients and Their Comparison with Obese and Overweight NAFLD.
    Chakrabarty M; Jha AN; Sharma DJ
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Features of Non-Alcoholic Fatty Liver Disease in the Non-Lean Population.
    Li MR; Li JZ; Li JY; Wang CC; Yuan RK; Ye LH; Liu YY; Liang XJ; Zhang HC; Liu ZQ; Zeng DY; Zhang XD; Wang DH; Li JQ; Li TY; Yang L; Cao Y; Pan Y; Lin XG; Pan CQ; Dai EH; Dong ZY
    Obes Facts; 2023; 16(5):427-434. PubMed ID: 37231905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Lipid metabolism in non-alcoholic fatty liver disease in patients with different body weights in mid-mountain conditions].
    Toktogulova NA; Sultanalieva RB; Tuhvatshin RR; Kaliev TK
    Ter Arkh; 2023 Jan; 94(12):1361-1366. PubMed ID: 37167179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic Fatty Liver Disease in Lean Subjects: Associations With Metabolic Dysregulation and Cardiovascular Risk-A Single-Center Cross-Sectional Study.
    Semmler G; Wernly S; Bachmayer S; Wernly B; Schwenoha L; Huber-Schönauer U; Stickel F; Niederseer D; Aigner E; Datz C
    Clin Transl Gastroenterol; 2021 Apr; 12(4):e00326. PubMed ID: 33821832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic Fatty Liver Disease in The Rotterdam Study: About Muscle Mass, Sarcopenia, Fat Mass, and Fat Distribution.
    Alferink LJM; Trajanoska K; Erler NS; Schoufour JD; de Knegt RJ; Ikram MA; Janssen HLA; Franco OH; Metselaar HJ; Rivadeneira F; Darwish Murad S
    J Bone Miner Res; 2019 Jul; 34(7):1254-1263. PubMed ID: 31074909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between muscle strength and advanced fibrosis in non-alcoholic fatty liver disease: a Korean nationwide survey.
    Kang S; Moon MK; Kim W; Koo BK
    J Cachexia Sarcopenia Muscle; 2020 Oct; 11(5):1232-1241. PubMed ID: 32638541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cigarette Smoking Increased Risk of Overall Mortality in Patients With Non-alcoholic Fatty Liver Disease: A Nationwide Population-Based Cohort Study.
    Charatcharoenwitthaya P; Karaketklang K; Aekplakorn W
    Front Med (Lausanne); 2020; 7():604919. PubMed ID: 33365321
    [No Abstract]   [Full Text] [Related]  

  • 19. Different effects of low muscle mass on the risk of non-alcoholic fatty liver disease and hepatic fibrosis in a prospective cohort.
    Choe HJ; Lee H; Lee D; Kwak SH; Koo BK
    J Cachexia Sarcopenia Muscle; 2023 Feb; 14(1):260-269. PubMed ID: 36403577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD).
    Golabi P; Stepanova M; Pham HT; Cable R; Rafiq N; Bush H; Gogoll T; Younossi ZM
    BMJ Open Gastroenterol; 2018; 5(1):e000198. PubMed ID: 29607054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.